文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

二价SARS-CoV-2 mRNA疫苗(XBB.1.5/BQ.1)在18岁及以上中国参与者中异源加强的安全性和免疫原性:一项随机、双盲、阳性对照1期试验

Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
PubMed 文献 · Vaccine · 2024-03-08

这项随机、双盲、阳性对照1期试验纳入200名已接受SARS-CoV-2基础免疫的健康成人,分别接种一剂SYS6006.32(二价XBB.1.5/BQ.1疫苗,N=100)或原型单价对照疫苗SYS6006(N=100)。SYS6006.32组和SYS6006组分别有61人(61.0%)和60人(60.0%)报告不良事件,多数为1级或2级,未观察到严重不良事件。接种后14天,SYS6006.32异源加强针对BA.5、XBB.1.5和EG.5诱导了强效活病毒中和抗体应答,几何平均滴度(GMT)分别增加17.1倍、34.0倍和48.0倍,假病毒中和抗体GMT分别增加12.2倍、32.0倍和35.1倍,且免疫原性优于SYS6006。

要点

  • SYS6006.32组61人(61.0%)和SYS6006组60人(60.0%)报告不良事件,多数为1级或2级,未观察到严重不良事件。
  • 接种后14天,SYS6006.32针对BA.5、XBB.1.5和EG.5的活病毒中和抗体GMT分别增加17.1倍、34.0倍和48.0倍。
  • SYS6006.32针对XBB.1.16、XBB.2.3和BA.2.86的假病毒中和抗体GMT较SYS6006高3至6倍,免疫原性优于SYS6006。

核心结论

  • SYS6006.32表现出良好的安全性特征,且免疫原性优于单价疫苗SYS6006。

研究设计与样本

  • 随机、双盲、阳性对照1期试验,200名已接受SARS-CoV-2基础免疫的健康成人随机接种一剂SYS6006.32(N=100)或SYS6006(N=100)。

主要发现

  • SYS6006.32组61人(61.0%)和SYS6006组60人(60.0%)报告不良事件,多数为1级或2级,最常见的注射部位和全身不良事件分别为疼痛和发热,未观察到严重不良事件。
  • 接种后14天,SYS6006.32针对BA.5、XBB.1.5和EG.5的活病毒中和抗体GMT分别增加17.1倍、34.0倍和48.0倍。
  • 接种后14天,SYS6006.32针对BA.5、XBB.1.5和EG.5的假病毒中和抗体GMT分别增加12.2倍、32.0倍和35.1倍。
  • SYS6006.32针对XBB.1.16、XBB.2.3和BA.2.86的假病毒中和抗体GMT较SYS6006高3至6倍。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants urges the development of new vaccines. We assessed the safety and immunogenicity of SYS6006.32, a bivalent vaccine (XBB.1.5/BQ.1), in healthy adults who had received SARS-CoV-2 primary vaccination. In a randomised, double-blinded, active-controlled trial, 200 participants were randomised to receive one dose of SYS6006.32 (N = 100) or a prototype-based, monovalent control vaccine SYS6006 (N = 100). Adverse events (AEs) were collected through the study. Immunogenicity was assessed by live-virus neutralising antibody (Nab) and pseudovirus Nab. 61 (61.0 %) and 60 (60.0 %) participants reported AE in the SYS6006.32 and SYS6006 groups, respectively. Most AEs were grade 1 or 2. Pain and fever were the most common injection-site and systemic AEs, respectively. No serious AEs were observed. SYS6006.32 heterologous boosting induced robust Nab responses against BA.5, XBB.1.5 and EG.5 with live-virus Nab geometric mean titres (GMTs) increased by 17.1-, 34.0-, and 48.0-fold, and pseudovirus Nab GMTs increased by 12.2-, 32.0-, and 35.1-fold, respectively, 14 days after vaccination. SYS6006.32 demonstrated a superior immunogenicity to SYS6006. SYS6006.32 also induced robust pseudovirus Nab responses against XBB.1.16, XBB.2.3, and BA.2.86, with GMTs 3- to 6-fold higher than those induced by SYS6006. In conclusion, SYS6006.32 showed good safety profile and superior immunogenicity to the monovalent vaccine SYS6006.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Su YW, Qiu YZ, Wang YH, et al. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine. 2024. PMID: 38461050. doi:10.1016/j.vaccine.2024.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。